S. A. Messer - Concepedia

Author

S. A. Messer

Also Known As

S A Messer, S Messer, S. A. MESSER, S. A. Messer, S. MESSER, S. Messer, S.A Messer, S.A. Messer, Shawn A Messer, Shawn A. Messer

214

Publications

21K

Citations

H-Index

Concepts

All Affiliations

University of Iowa JMI Laboratories Tufts University

About

S. A. Messer is an author at University of Iowa specializing in medicine, antimicrobial resistance, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	61	100	10.2K
2	Health Sciences	40	47	5K
3	Public Health	4	4	1.1K
4	Biology	4	4	333
5	Allergy	1	1	21

S. A. Messer

180

Publications

20.8K

Citations

H-Index

Page 1

	Year	Citations
Attributable Mortality of Nosocomial Candidemia, Revisited Stephen H. Gillespie, Kyungwon Lee, Jeffery Vande Berg, Clinical Infectious Diseases	2003	1.1K
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations Barbara D. Alexander, Melissa D. Johnson, Christopher D. Pfeiffer, Clinical Infectious Diseases	2013	765
International Surveillance of Bloodstream Infections Due to <i>Candida</i> Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program Michael A. Pfaller, Daniel J. Diekema, Ronald N. Jones, Journal of Clinical Microbiology	2001	523
National Surveillance of Nosocomial Blood Stream Infection Due to Species of Candida Other than Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE Program Michael A. Pfaller, Ronald N. Jones, S. A. Messer, Diagnostic Microbiology and Infectious Disease Antifungal AgentsScope ProgramCandida AlbicansClinical EpidemiologyHealthcare-associated Infection	1998	424
Antifungal Susceptibilities of <i>Candida</i> Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases Sandra S. Richter, Rudolph P. Galask, S. A. Messer, Journal of Clinical Microbiology	2005	417
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of <i>Aspergillus</i> spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 Michael A. Pfaller, S. A. Messer, R. J. Hollis, Antimicrobial Agents and Chemotherapy	2002	401
In Vitro Susceptibility of Invasive Isolates of <i>Candida</i> spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance Michael A. Pfaller, L. Boyken, R. J. Hollis, Journal of Clinical Microbiology Microbial PathogensVitro SusceptibilityClinical MycologyDrug ResistanceInfection Control	2007	385
Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study Daniel J. Diekema, S. A. Messer, Angela B. Brueggemann, Journal of Clinical Microbiology	2002	384
Bloodstream Infections Due to <i>Candida</i> Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 Michael A. Pfaller, Ronald N. Jones, Gary V. Doern, Antimicrobial Agents and Chemotherapy Diagnostic MycologyClinical MycologyLatin AmericaU.s. IsolatesInternational Program	2000	377
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata Michael A. Pfaller, Mariana Castanheira, Shawn R. Lockhart, Journal of Clinical Microbiology	2012	369

Page 1